Advancing Understanding of Non-Small Cell Lung Cancer with Multiplexed Antibody-Based Spatial Imaging Technologies
Simon Gray1,2, Christian H Ottensmeier1,2
1Department of Molecular and Clinical Cancer Medicine, Faculty of Health and Life Sciences, University of Liverpool, Ashton St., Liverpool L69 3GB, UK.
Abstract:
Non-small cell lung cancer (NSCLC) remains a cause of significant morbidity and mortality, despite significant advances made in its treatment using immune checkpoint inhibitors (ICIs) over the last decade; while a minority experience prolonged responses with ICIs, benefit is limited for most patients. The development of multiplexed antibody-based (MAB) spatial tissue imaging technologies has revolutionised analysis of the tumour microenvironment (TME), enabling identification of a wide range of cell types and subtypes, and analysis of the spatial relationships and interactions between them. Such study has the potential to translate into a greater understanding of treatment susceptibility and resistance, factors influencing prognosis and recurrence risk, and identification of novel therapeutic approaches and rational treatment combinations to improve patient outcomes in the clinic. Herein we review studies that have leveraged MAB technologies to deliver novel insights into the TME of NSCLC.
Insights
Multiplexed antibody-based (MAB) spatial imaging reveals new insights into the non-small cell lung cancer (NSCLC) tumor microenvironment (TME). This technology helps understand treatment resistance and identify new therapeutic strategies for NSCLC patients.
Area of Science:
- Oncology
- Immunology
- Biotechnology
Background:
- Non-small cell lung cancer (NSCLC) presents a significant health burden globally.
- Immune checkpoint inhibitors (ICIs) have improved NSCLC treatment, but responses are limited for many patients.
- Understanding the tumor microenvironment (TME) is crucial for improving NSCLC therapies.
Purpose of the Study:
- To review studies utilizing multiplexed antibody-based (MAB) spatial tissue imaging.
- To explore novel insights into the NSCLC tumor microenvironment (TME) gained from MAB technologies.
- To highlight the potential of MAB in understanding treatment response and guiding future therapies.
Main Methods:
- Leveraging multiplexed antibody-based (MAB) spatial tissue imaging technologies.
- Analyzing diverse cell types, subtypes, and their spatial interactions within the NSCLC TME.
- Reviewing existing literature on MAB applications in NSCLC research.
Main Results:
- MAB technologies enable detailed characterization of the NSCLC TME.
- Spatial analysis reveals complex cell-cell interactions influencing treatment outcomes.
- Identification of potential biomarkers for ICI response and resistance.
Conclusions:
- MAB spatial imaging offers a powerful approach to dissect the NSCLC TME.
- This technology can enhance understanding of treatment susceptibility and resistance mechanisms.
- MAB has the potential to drive the development of novel therapeutic strategies and combinations for NSCLC.
